NUESTRA EXPERIENCIA, SU CALIDAD DE VIDA

Anunciamos el lanzamiento del sitio www.bendavar.com, donde podrán encontrar toda la información relacionada con el producto, sus indicaciones y una biblioteca virtual con diversos artículos de interés para el profesional.

Productos destacados

VIDAZA ®
Ver más
BENDAVAR 100 MG
Ver más
KYPROLIS
Ver más

Biblioteca

    • Pierre Fenaux

      Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute...

      Ver PDF (245 kb)
    • Emmanuel Raffoux

      Epigenetic Therapy with 5-Azacitidine, Valproic Acid, and ATRA in Patients with High-Risk AML or MDS: Results of the French VIVEDEP Phase II Study

      Ver DOC (49 kb)
    • GAUTAM BORTHAKUR

      Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk...

      Ver PDF (184 kb)
    • D. A. Pollyea

      An early-phase study of azacitidine and lenalidomide for untreated elderly acute myeloid leukemia (AML) patients.

      Ver PDF (12 kb)
    • E. Bustinza-Linares

      Phase I trial of sequential azacitidine and valproic acid plus carboplatin in the treatment of patients with advanced...

      Ver PDF (11 kb)

    • Ronit Gurion

      5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome - a systematic review and meta-analysis...

      Ver PDF (237 kb)
    • Lewis R. Silverman

      Further Analysis of Trials With Azacitidine in Patients With Myelodysplastic Syndrome: Studies 8421, 8921, and 9221 by...

      Ver PDF (101 kb)
    • Lewis R. Silverman

      Randomi zed Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B...

      Ver PDF (184 kb)
    • Pierre Fenaux

      Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes...

      Ver PDF (1153 kb)

    • Eric Tse

      Clofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia

      Ver PDF (99 kb)
    • Kavita Radhakrishnan

      Leukemia, Myelodysplasia, and Transplantation

      Low day 100 transplant-related mortality (TRM)...

      Ver PDF (28 kb)
    • Michael Mathisen

      Leukemia, Myelodysplasia, and Transplantation

      Interim results of a phase I/II randomized study of clofarabine...

      Ver PDF (27 kb)
    • A Pession

      Use of clofarabine for acute childhood leukemia

      Ver PDF (159 kb)
    • Anjali S. Advani

      Southwest Oncology Group Study S0530: A Phase 2 Trial of Clofarabine and Cytarabine for Relapsed or Refractory Acute...

      Ver PDF (586 kb)

    • S Imbergamo

      [P0673] CLOFARABINE AS A SALVAGE THERAPY AND A BRIDGE TO TRANSPLANTATION IN PATIENTS WITH HIGH RISK ACUTE...

      Ver DOC (157 kb)
    • Sima Jeha

      Phase II Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia

      Ver PDF (91 kb)
    • Carlos Enrique Vigil

      Leukemia, Myelodysplasia, and Transplantation

      A phase II study of clofarabine and daunorubicin...

      Ver PDF (27 kb)
    • EDWARD AGURA

      Report of a Phase II Study of Clofarabine and Cytarabine in De Novo and Relapsed and Refractory AML Patients and in Selected Elderly...

      Ver PDF (265 kb)
    • Theresa M Harned Paul S Gaynon

      Treating refractory leukemias in childhood, role of clofarabine

      Ver PDF (116 kb)

      Linfoma No Hodgkin

    • ASCO

      Sven De Vos

      A phase III randomized double-blind placebo-controlled study evaluating the LNH

      Ver PDF (28 kb)
    • ASCO

      David MacDonald

      Different safety profiles of first-line bendamustine-rituximab (BR) R-CHOP and LNH

      Ver PDF (40 kb)
    • ASCO

      Ian Flinn

      Secondary efficacy subanalysis by histology from the phase III BRIGHT study LNH

      Ver PDF (38 kb)
    • ASCO

      John Leonard

      Tolerability and activity of combinations of the PI3Kd inhibitor idelalisib (GS-1101) LNH

      Ver PDF (32 kb)
    • R. Van der Jagt, P. Laneuville, D. MacDonald y otros.

      A Canadian perspective on bendamustine for the treatmen...

      Ver PDF (452 kb) Ver PDF II (32 kb)

    • Mathias J Rummel

      Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell...

      Ver PDF (312 kb)
    • Remy Gressin

      Multicenter, phase II study of bendamustine in refractory or relapsed T-cell lymphoma: The BENTLY trial.

      Ver PDF (28 kb)
    • Mathias Rummel, MD, PhD, Giessen, Germany

      Reassessing the Standard of Care in Indolent Lymphoma: A Clinical Update to Improve Clinical Practice

      Ver PDF (948 kb)
    • Jonathan W. Friedberg

      Bendamustine in Patients With Rituximab-Refractory Indolent and Transformed Non-Hodgkin’s Lymphoma: Results

      Ver PDF (117 kb)
    • Brad S. Kahl

      Bendamustine Is Effective Therapy in Patients With Rituximab-Refractory, Indolent B-cell Non-Hodgkin Lymphoma

      Ver PDF (185 kb)

    • K. Sue Robinson

      Phase II Multicenter Study of Bendamustine Plus Rituximab in Patients With Relapsed Indolent...

      Ver PDF (118 kb)

    • E. Weidmann

      Bendamustine is effective in relapsed or refractory aggresive non-Hodgking´s lymphoma

      Ver PDF (68 kb)

    • Georg Hess

      697 Temsirolimus in Combination with Bendamustine and Rituximab for the Treatment of Relapsed Mantle Cell...

      Ver PDF (142 kb)
    • Nathan H. Fowler

      778 Results of a Phase II Study with Bendamustine and Ofatumumab in Untreated Indolent B-Cell Non-Hodgkin’s Lymphoma

      Ver PDF (164 kb)
    • Maurizio Bendandi

      2691 Single Agent Bendamustine Is An Effective Pre-Vaccine Treatment for Patients with Relapsed Follicular Lymphoma

      Ver PDF (140 kb)

      Leucemia Linfática Crónica

    • Susan Mary O'Brien

      Combination of the Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 with bendamustine...

      Ver PDF (139 kb)
    • K Holtzer-Goor

      [P1089] Modelling the 10-Year cost effectiveness of Bendamustine as first line treatment...

      Ver PDF (596 kb)
    • Georg Guenther

      Bendamustine retreatment of CLL in the outpatient setting.

      Ver PDF (35 kb)
    • William G. Wierda

      901 A Phase I/II Trial of Fludarabine, Bendamustine, and Rituximab (FBR) Chemoimmuno-therapy...

      Ver PDF (157 kb)
    • Rudolf Weide

      1615 Retherapy with Bendamustine-Containing Regimens in Patients with Relapsed/Refractory CLL and Indolent Lymphomas...

      Ver PDF (119 kb)

    • Thomas J. Kipps

      3904 Navitoclax (ABT-263) Plus Fludarabine / Cyclophosphamide / Rituximab (FCR)...

      Ver PDF (151 kb)

    • Kathryn S. Kolibaba

      3914 Demographics, Treatment Patterns, Safety, and Real-World Effectiveness in Patients ≥70 Years...

      Ver PDF (173 kb)
    • Manuela A. Bergmann

      Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia...

      Ver PDF (170 kb)
    • Saad Jamshed, Bruce D Cheson

      Role of bendamustine in the treatment of chronic lymphocytic leukemia

      Ver PDF (113 kb)
    • Wolfgang U. Knauf,

      Phase III Randomized Study of Bendamustine Compared With Chlorambucil in Previously Untreated Patients...

      Ver PDF (146 kb)

    • ASCO

      Herbert Aaron Eradat

      A phase III randomized double-blind placebo-controlled study evaluating the LLC

      Ver PDF (31 kb)
    • ASCO

      Jacqueline Claudia Barrientos

      Update on a phase I study of the selective PI3Kd inhibitor idelalisib (GS-1101) in LLC

      Ver PDF (32 kb)
    • ASCO

      Betty Y Chang

      Use of tumor genomic profiling to reveal mechanisms of resistance to the BTK inhibitor ibrutinib in chronic LLC.

      Ver PDF (28 kb)

      Mieloma Múltiple

    • W Pönisch

      Combined Bendamustine, prednisolone and lenalidomine in patients with refractory or relapsed multiple...

      Ver PDF (225 kb)
    • Philippe Rodon

      Bendamustine, bortezomib, and dexamethasone (BVD) in elderly patients with relapsed/refractory multiple myeloma...

      Ver PDF (29 kb)
    • Suzanne Lentzsch

      Bendamustina en Mieloma Múltiple
      304 Combination of Bendamustine, Lenalidomide, and Dexamethasone (BLD) in Patients...

      Ver PDF (161 kb)
    • James R. Berenson

      Bendamustina en Mieloma Múltiple
      1857 Bendamustine Combined with Bortezomib Has Efficacy in Patients with Relapsed...

      Ver PDF (154 kb)
    • Wolfram Pönisch

      Bendamustina en Mieloma Múltiple
      1933 Impact of Bendamustine Pretreatment on Stem Cell Mobilization and...

      Ver PDF (123 kb)

    • Heinz Ludwig

      Bendamustina en Mieloma Múltiple
      2928 Bortezomib-Bendamustine-Dexamethasone in Patients with Relapsed...

      Ver PDF (167 kb)
    • Wolfram Pönisch

      Bendamustina en Mieloma Múltiple
      2938 Successful Treatment with Bortezomib in Combination with Bendamustine...

      Ver PDF (133 kb)
    • Jesus G. Berdeja

      Bendamustina en Mieloma Múltiple
      2943 A Phase II Trial of Combined Bendamustine, Bortezomib and Dexamethasone...

      Ver PDF (143 kb)

      Indolentes y del Manto

    • Carlos Visco

      Combination of Rituximab, Bendamustine, and Cytarabine for Patients With Mantle-Cell Non-Hodgkin Lymphoma...

      Ver DOC (30 kb)
    • Wayne Su

      Cost-effectiveness analysis of bendamustine plus rituximab versus CHOP-R in treatment-naive patients with mantle cell (MCL)...

      Ver PDF (27 kb)
    • Georg Hess

      Bendamustina en Linfomas de Manto
      697 Temsirolimus in Combination with Bendamustine and Rituximab for the Treatment of...

      Ver PDF (142 kb)
    • Mats Jerkeman

      Bendamustina en Linfomas de Manto
      700 Lenalidomide, Bendamustine, and Rituximab As First-Line Therapy for Patients...

      Ver PDF (140 kb)
    • Michele Magni

      Bendamustina en Linfomas de Manto
      1647 Safety, Tolerability and Activity of Ofatumumab, Bendamustine...

      Ver PDF (163 kb)

    • Carlo Visco

      Bendamustina en Linfomas de Manto
      2677 Rituximab, Bendamustine and Cytarabine (R-BAC) Is a Very Active Regimen in patients...

      Ver PDF (130 kb)
    • Jonathan W. Friedberg

      Bendamustina en Linfomas de Manto
      The combination of bendamustine, bortezomib, and rituximab for patients with relapsed...

      Ver PDF (223 kb)
    • K. Sue Robinson

      Bendamustina en Linfomas de Manto
      Phase II Multicenter Study of Bendamustine Plus Rituximab in Patients With Relapsed...

      Ver PDF (118 kb)
    • Mathias J. Rummel

      Bendamustina en Linfomas de Manto
      Bendamustine Plus Rituximab Is Effective and Has a Favorable Toxicity Profile in the Treatment of...

      Ver PDF (282 kb)
    • ASCO

      Michael Wang

      A phase III study of ibrutinib in combination with bendamustine and rituximab (BR) in elderly patients with newly diagnosed MCL.

      Ver PDF (28 kb)

    • ASCO

      Nina D. Wagner-Johnston

      Preliminary results of PI3Kd inhibitor idelalisib (GS-1101) treatment in combination...

      Ver PDF (31 kb)

      EHA-ASH 2013

    • Matthew Woods

      THE EFFICACY AND SAFETY OF FIRST–LINE TREATMENTS FOR CHRONIC LYMPHOCYTIC LEUKEMIA

      Ver PDF (376 kb)
    • Novella Pugliese

      BENDAMUSTINE–BASED THERAPY IS EFFECTIVE AND HAS A FAVOURABLE TOXICITY PROFILE IN THE TREATMENT OF REFRACTORY AND...

      Ver PDF (484 kb)
    • Salvatore Improta

      BENDAMUSTINE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY WALDENSTRÖM'S MACROGLOBULINEMIA

      Ver PDF (373 kb)
    • Matteo Pelosini

      LOW DOSE BENDAMUSTINE IN LYMPHOPROLIFERATIVE DISEASE: A SINGLE CENTER EXPERIENCE

      Ver PDF (329 kb)
    • Clara De Risi

      SAFETY OF BENDAMUSTINA INCLUDING DHAP REGIMEN AS SALVAGE THERAPY IN MULTIRESISTANT LYMPHOMA PATIENTS

      Ver PDF (404 kb)

    • Philippe Rodon

      BENDAMUSTINE, BORTEZOMIB AND DEXAMETHASONE (BVD) IN ELDERLY MM PROGRESSIVE AFTER 1ST LINE THERAPY (IFM 2009–01 TRIAL)

      Ver PDF (381 kb)
    • Alessandro Isidori

      BENDAMUSTINE, ETOPOSIDE, CYTARABINE AND MELPHALAN (BEEAM) FOLLOWED BY AUTOLOGOUS STEM CELL...

      Ver PDF (380 kb)
    • James Brockbank

      A SYSTEMATIC REVIEW OF ECONOMIC ANALYSES, UTILITY, RESOURCE USE, AND COST ESTIMATES OF FIRST–LINE TREATMENTS FOR...

      Ver PDF (377 kb)
    • Enrique Ocio San Miguel

      EX VIVO PHARMACOLOGICAL EVALUATION OF 19 DRUGS IN AN AVERAGE OF 50 MULTIPLE MYELOMA PATIENTS USING...

      Ver PDF (364 kb)
    • Heinz Ludwig

      TOXICITY PROFILE DURING TREATMENT WITH BENDAMUSTINE BORTEZOMIB DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY

      Ver PDF (463 kb)

    • Caterina Patti

      INTENSIFIED PROGRAM INCLUDING BENDAMUSTINE, HIGH DOSE THERAPY AND AUTOGRAFT FOR PATIENTS WITH RELAPSED OR...

      Ver PDF (304 kb)
    • Carola Boccomini

      BRIEF RITUXIMAB, BENDAMUSTINE, MITOXANTRONE (R–BM) INDUCTION FOLLOWED BY RITUXIMAB CONSOLIDATION...

      Ver PDF (461 kb)
    • Claudio Cerchione

      BENDAMUSTINE : A NEW OPTION FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA

      Ver PDF (298 kb)
    • Takae Kohara

      EVALUATION OF EFFICACY AND SAFETY OF BENDAMUSTINE TREATMENT IN OSAKA LYMPHOMA STUDY GROUP(OLSG)...

      Ver PDF (334 kb)
    • Martin Becker

      NON–INTERVENTIONAL STUDY BE–1ST: FIRST LINE THERAPY WITH BENDAMUSTINE IN ADVANCED INDOLENT NON–HODGKIN...

      Ver PDF (535 kb)

    • William G. Wierda & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 437

      Ver PDF (367 kb)
    • Heinz Ludwig & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 943

      Ver PDF (432 kb)
    • Ian W. Flinn & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 1624

      Ver PDF (423 kb)
    • Francisco Javier Peñalver & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 1639

      Ver PDF (435 kb)
    • Stefano Sacchi & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 1851

      Ver PDF (438 kb)

    • Wolfram Poenisch & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 1855

      Ver PDF (427 kb)
    • Antonella Anastasia & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 1914

      Ver PDF (431 kb)
    • Mazyar Shadman & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 2622

      Ver PDF (482 kb)
    • Francisco Javier Peñalver & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 1639

      Ver PDF (435 kb)
    • Carola Boccomini & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 2720

      Ver PDF (435 kb)

    • Mathias J. Rummel & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 2739

      Ver PDF (512 kb)
    • Veronique Leblond & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 2744

      Ver PDF (445 kb)
    • Mazyar Shadman & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 2622

      Ver PDF (482 kb)
    • Georg Günther & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 2905

      Ver PDF (530 kb)
    • Eric Sanchez & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 2952

      Ver PDF (432 kb)

    • Pellegrino Musto & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 2971

      Ver PDF (344 kb)
    • Julie E. Chang & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 3647

      Ver PDF (432 kb)
    • Antonella Anastasia & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 3652

      Ver PDF (428 kb)
    • Frederick Lansigan & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 3657

      Ver PDF (352 kb)
    • Myron S. Czuczman & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 3662

      Ver PDF (438 kb)

    • Wolfgang Ulrich Knauf & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 3666

      Ver PDF (510 kb)
    • Martin JS Dyer & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 3686

      Ver PDF (441 kb)
    • Antonio Salar & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 3691

      Ver PDF (349 kb)
    • Francesco Zaja & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 3922

      Ver PDF (444 kb)
    • Beatriz Aguado Bueno & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 4035

      Ver PDF (343 kb)

    • Philippe Rodon & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 4044

      Ver PDF (432 kb)
    • Jesus G. Berdeja & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 4047

      Ver PDF (441 kb)
    • Giovanni Palladini & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 4057

      Ver PDF (433 kb)
    • Damian J. Green & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 4126

      Ver PDF (432 kb)
    • Stefano Sacchi & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 1851

      Ver PDF (437 kb)

    • Mazyar Shadman & Otros

      Blood Abstracts: 54th ASH Annual Meeting Abstracts; Vol. 120, Issue 21, 16 Nov 2012

      Abstract 2622

      Ver PDF (482 kb)

      Otros Artículos

    • Carlos Visco

      Combination of Rituximab, Bendamustine, and Cytarabine for Patients With Mantle-Cell Non-Hodgkin Lymphoma...

      Ver DOC (30 kb)
    • John Leonard

      A randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma.

      Ver PDF (1001 kb)
    • Christine Marie Lovly

      A phase II study of second-line bendamustine in relapsed or refractory small cell lung cancer (SCLC).

      Ver PDF (25 kb)
    • A de la Fuente

      [P1669] BENDAMUSTINE IN THE TREATMENT OF AGGRESSIVE NON HODGKIN LYMPHOMA. A RETROSPECTIVE ANALYSIS IN SPAIN

      Ver PDF (124 kb)
    • Christopher Fraser

      Bendamustina en Leucemia Aguda
      3602 Open-Label Bendamustine for Pediatric Patients with Relapsed or Refractory...

      Ver PDF (151 kb)

    • Jack M. Lionberger

      Bendamustina en LMA
      1552 Innovative Phase I/II Statistical Design in Combination Chemotherapy That Combines Toxicity and Efficacy...

      Ver PDF (150 kb)
    • Leukemia Research

      Bendamustina en Linfomas Hodgkin de Alto Grado
      Efficacy of bendamustine as salvage treatment in an heavily pre-treated

      Ver PDF (112 kb)
    • Issa F Khouri

      894 Nonmyeoablative Allogeneic Conditioning with Bendamustine in Combination with Fludarabine and Rituximab for...

      Ver PDF (143 kb)
    • Anne-Charlotte Dubbelman

      2476 An Open-Label Phase I Pharmacokinetic Study of [14c] Bendamustine in Patients with...

      Ver PDF (144 kb)
    • Lorenzo M. Leoni

      Bendamustine (Treanda) Displays a Distinct Pattern of Cytotoxicity and Unique Mechanistic Features Compared with Other...

      Ver PDF (483 kb)

    • Lorenzo M. Leoni

      Bendamustine: Rescue of an Effective Antineoplastic Agent From the Mid-Twentieth Century

      Ver PDF (534 kb)
    • G Benevolo

      [P0208] SAFETY AND EFFICACY OF BENDAMUSTINE THERAPY IN WALDENSTROM MACROGLOBULINEMIA

      Ver PDF (70 kb)
    • ASCO

      Daniel Joseph Allendorf

      Phase I/IIa study of the novel combination of bendamustine with irinotecan followed by etoposide and carboplatin...

      Ver PDF (36 kb)

    • David S. Siegel

      A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma...

      Open PDF (550 kb)